Forward Management LLC grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,025 shares of the medical instruments supplier’s stock after acquiring an additional 32 shares during the quarter. Forward Management LLC’s holdings in Becton, Dickinson and were worth $1,176,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in BDX. Palisade Asset Management LLC lifted its holdings in Becton, Dickinson and by 0.5% in the second quarter. Palisade Asset Management LLC now owns 51,186 shares of the medical instruments supplier’s stock worth $9,987,000 after purchasing an additional 245 shares during the period. Global X Management Co. LLC lifted its holdings in Becton, Dickinson and by 18.2% in the second quarter. Global X Management Co. LLC now owns 3,804 shares of the medical instruments supplier’s stock worth $742,000 after purchasing an additional 586 shares during the period. HL Financial Services LLC lifted its holdings in Becton, Dickinson and by 21.2% in the second quarter. HL Financial Services LLC now owns 6,673 shares of the medical instruments supplier’s stock worth $1,302,000 after purchasing an additional 1,166 shares during the period. Lakeview Capital Partners LLC lifted its holdings in Becton, Dickinson and by 2.5% in the second quarter. Lakeview Capital Partners LLC now owns 2,070 shares of the medical instruments supplier’s stock worth $404,000 after purchasing an additional 50 shares during the period. Finally, Advisor Partners LLC lifted its holdings in Becton, Dickinson and by 7.1% in the second quarter. Advisor Partners LLC now owns 3,564 shares of the medical instruments supplier’s stock worth $695,000 after purchasing an additional 235 shares during the period. 87.43% of the stock is owned by institutional investors.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 203.70 on Monday. The firm has a market capitalization of $46.35 billion, a P/E ratio of 58.99 and a beta of 1.06. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63. The firm has a 50-day moving average of $200.12 and a 200-day moving average of $190.74.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same quarter last year, the business earned $2.35 earnings per share. On average, equities analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.43%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is 83.43%.

WARNING: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/11/forward-management-llc-has-1-18-million-stake-in-becton-dickinson-and-company-bdx.html.

Several research firms recently weighed in on BDX. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Cowen and Company reaffirmed a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. Barclays PLC reaffirmed an “equal weight” rating and issued a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Finally, Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Monday, August 7th. One analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Becton, Dickinson and presently has an average rating of “Buy” and an average target price of $195.79.

In related news, insider Gary M. Cohen sold 15,044 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $200.43, for a total value of $3,015,268.92. Following the transaction, the insider now owns 95,270 shares in the company, valued at $19,094,966.10. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,605 shares of company stock worth $9,718,986. 1.40% of the stock is owned by company insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.